Bernardo Cortese (Milan, Italy) talks to BLearning about the EASTBOURNE registry, which he states is the “largest registry ever on a drug-coated balloon (DCB) for coronary applications”.
Cortese presented the interim results in a late-breaking session at EuroPCR 2019 (21–24 May, Paris, France), which looked at the “feasibility, safety and the long-term efficacy” of a novel sirolimus-coated balloon.
The interim analysis, of 650 patients at one-month follow-up, found “very low clinical events, no safety signals and very good efficacy”. Additionally, in a limited population of 207 patients with 12-month follow-up, the primary endpoint results were “also low” and there was a 2.4 rate of target lesion revascularisation – leading Cortese to remark that the preliminary signals are “very good with this device”.
These results, notes Cortese, come at “a very important time for DCBs” because there are “some signals of lower safety at the long-term for peripheral DCB and paclitaxel-eluting devices”.
Add comment